PAN 301-1

Drug Profile

PAN 301-1

Alternative Names: HAAH-1Lambda phage vaccine; HAAH-2Lambda phage vaccine; HAAH-3Lambda phage vaccine; nanoparticle HAAH vaccine; PAN-301-1

Latest Information Update: 13 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Panacea Pharmaceuticals
  • Class Bacteriophages; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 17 Jan 2017 Phase-I clinical trials in Prostate cancer (Second-line therapy or greater) in USA (Intradermal)
  • 08 Dec 2015 Panacea intends to file an IND application with the FDA in USA for Cancer in first quarter of 2016
  • 08 Dec 2015 Panacea plans a phase I trial in Cancer in second quarter of 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top